Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Byron Donalds

Representative Byron Donalds (Republican-Florida) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on April 2nd. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/2/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 3/20/2026.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 3/20/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 3/13/2026.

Eli Lilly and Company Trading Up 3.0%

Shares of Eli Lilly and Company stock traded up $29.59 on Tuesday, hitting $1,017.68. 3,792,229 shares of the company’s stock traded hands, compared to its average volume of 3,192,277. The firm’s 50-day moving average price is $940.00 and its two-hundred day moving average price is $999.39. The stock has a market capitalization of $958.39 billion, a PE ratio of 36.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently made changes to their positions in the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the last quarter. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $30,000. Finally, 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Leerink Partners dropped their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Scotiabank restated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Finally, Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $1,218.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary continue to highlight Eli Lilly’s leadership in the obesity boom, with strong sales momentum in key products such as Mounjaro and broader confidence that the company still has room to run. Article Title
• Positive Sentiment: Stat News reported that Eli Lilly tops prominent rankings for pharma R&D performance, reinforcing the view that the company’s pipeline and innovation engine remain among the best in the industry. Article Title
• Positive Sentiment: Eli Lilly also announced it completed a key olomorasib drug-interaction study, which helps clarify next steps for its KRAS pipeline and supports the long-term growth story beyond obesity drugs. Article Title
• Neutral Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations event that could provide more details on strategy and pipeline updates. Article Title
• Negative Sentiment: The U.S. Supreme Court declined to hear Eli Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million award and keeping legal/compliance risk in focus. Article Title
• Negative Sentiment: Related coverage noted that the ruling could raise scrutiny around Medicaid rebates and dividend implications, adding a modest overhang even as the core business remains strong. Article Title

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.